Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare disease drugs largely countered declining sales of its older multiple ...

Piper Sandler raised the firm’s price target on Biogen (BIIB) to $118 from $115 and keeps a Neutral rating on the shares. The ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why BIIB stock is a hold.

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

Biogen Inc. closed 34.53% below its 52-week high of $207.59, which the company achieved on August 21st.

Biogen agreed to buy Reata Pharmaceuticals for $7.3 billion, offering the company access to a drug that fits perfectly with its goals of treating both neuromuscular and rare diseases.

Biotechnology giant Biogen Inc. BIIB 4.86% has drawn takeover interest from drug companies including Merck MRK 3.00% & Co. and Allergan PLC, raising the possibility of another huge deal in the ...

As Biogen’s new CEO Chris Viehbacher pores over Biogen’s books and scouts out M&A deals, he may have one advantage his predecessor didn’t: a good relationship with his board of directors.